FDA plans to eye "corrective" DTC

Share this article:

FDA has outlined plans to study the use of corrective DTC TV ads as a way of remedying deceptive advertising. The agency wants to know how exposure to a combination of original and corrective ads affects message recall, message comprehension, perceived efficacy and risk and intent to ask a doctor about the drug. It also wants to find out how comprehension might relate to theme and visual elements in the advertisements as well as to the length of delay between the original ad and the corrective ad.

The agency plans to conduct 6,650 online interviews for the study. Ads will feature fake products for asthma and weight loss.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions